AI Article Synopsis

  • A systematic review and meta-analysis were conducted to evaluate the safety and efficacy of osimertinib in non-small-cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor mutations.
  • The analysis included 15 studies with 594 patients, revealing common mutations such as G719X and L861Q, and determining key metrics like a 51.30% objective response rate (ORR) and a median progression-free survival of 9.71 months.
  • Osimertinib was found to be generally safe, with only 21.77% of patients experiencing serious adverse events, showing promise for treating NSCLC with these uncommon mutations.

Article Abstract

Purpose: The activity of osimertinib is not fully characterized in non-small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor () mutations. Therefore, we conducted a systematic review and meta-analysis to assess the safety and efficacy of osimertinib in patients with NSCLC harboring uncommon somatic mutations.

Methods: PubMed, Embase, and the Cochrane Library were searched for eligible studies reporting the efficacy and safety of osimertinib in NSCLC with uncommon mutations defined as any mutations other than exon 19 deletion, L858R and T790M mutations, and exon 20 insertion, except when in compound. Then, we performed a meta-analysis to pool survival outcomes and antitumoral activity, including intracranial (ic) response and adverse events.

Results: Fifteen studies comprising 594 patients were included. The most frequently observed uncommon solitary mutations were G719X in 25% (81/327) of patients and L861Q in 21% (69/327). The most common compound mutations were G719X with T790M in 12% (23/192) of patients and G719X with S768I in 11% (22/192). Pooled analysis showed an objective response rate (ORR) of 51.30% (95% CI, 45.80 to 56.81), a disease control rate (DCR) of 90.11% (95% CI, 86.27 to 92.96), a median progression-free survival of 9.71 months (95% CI, 7.96 to 11.86), and a median overall survival of 16.79 months (95% CI, 9.93 to 28.39). icORR was 45.96% (95% CI, 30.18 to 62.17), and icDCR was 95.76% (95% CI, 69.84 to 100). Osimertinib was well tolerated with a frequency of grade 3 or more adverse events of 21.77% (95% CI, 6.24 to 43.33).

Conclusion: Osimertinib demonstrated robust response in NSCLC harboring uncommon mutations, without unanticipated safety concerns.

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.24.00331DOI Listing

Publication Analysis

Top Keywords

safety efficacy
8
efficacy osimertinib
8
osimertinib patients
8
non-small-cell lung
8
lung cancer
8
epidermal growth
8
growth factor
8
factor receptor
8
mutations
8
receptor mutations
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!